Portfolio company
LAVA Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops bispecific antibodies that engage gamma-delta T cells to treat hematological and solid cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
OPS-γδ
This company develops an engineered gamma delta T cell therapy platform to treat patients with solid tumours.
Ypsilon Therapeutics
The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Adicet Bio
Adicet Bio develops allogeneic gamma delta T cell therapies for patients with autoimmune diseases and cancer.
Cytospire Therapeutics
This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.
Zelluna
This company develops T cell receptor guided natural killer cell therapies to treat patients with solid cancers.
Laigo Bio
This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.
CDR-Life
The company develops antibody-based T cell engagers to treat patients with solid tumours and autoimmune diseases.